Cargando…
Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis
OBJECTIVE: To systematically evaluate the efficacy and safety of Huangqin Tang (HQT) combined with mesalazine for the treatment of ulcerative colitis (UC). METHODS: The China Knowledge Network, Wanfang Data, VIP, PubMed, SinoMed, Embase, and Cochrane Library databases were searched for randomized co...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388247/ https://www.ncbi.nlm.nih.gov/pubmed/35990830 http://dx.doi.org/10.1155/2022/2175913 |
_version_ | 1784770183169048576 |
---|---|
author | Pan, Chengyu Liu, Mengru Li, Hui Wei, Lanfu Wang, Pengcheng Wu, Kexuan Ji, Xing Gu, Limei Tian, Yaozhou |
author_facet | Pan, Chengyu Liu, Mengru Li, Hui Wei, Lanfu Wang, Pengcheng Wu, Kexuan Ji, Xing Gu, Limei Tian, Yaozhou |
author_sort | Pan, Chengyu |
collection | PubMed |
description | OBJECTIVE: To systematically evaluate the efficacy and safety of Huangqin Tang (HQT) combined with mesalazine for the treatment of ulcerative colitis (UC). METHODS: The China Knowledge Network, Wanfang Data, VIP, PubMed, SinoMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) of UC with HQT in Chinese and English. The search time was from the establishment of the database to October 2021. The included literature was evaluated for data extraction and risk of bias, efficacy and safety were evaluated using the RevMan5.3 software, and the quality of evidence was evaluated using GRADE. RESULTS: Six studies with a total of 565 subjects were included, and a meta-analysis showed that HQT combined with mesalazine for UC significantly improved the cure rate (RR = 1.56, 95% CI [1.23, 1.98), P=0.0003) and overall efficacy rate (RR = 1.24, 95% CI [1.14, 1.35], P=0.00001), which significantly reduced the clinical symptom scores; however, all had high heterogeneity. HQT combined with mesalazine modulated the patients' serum IL-6, IL-10, IgA, and IgG levels. HQT combined with mesalazine for UC tended to reduce adverse effects; however, the difference was not statistically significant. All GRADE ratings of the quality of evidence were of low quality. CONCLUSIONS: HQT combined with mesalazine in the treatment of UC significantly improved the cure rate and overall treatment efficiency and regulated the expression levels of serum IL-6, IL-10, IgA, and IgG. |
format | Online Article Text |
id | pubmed-9388247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-93882472022-08-19 Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis Pan, Chengyu Liu, Mengru Li, Hui Wei, Lanfu Wang, Pengcheng Wu, Kexuan Ji, Xing Gu, Limei Tian, Yaozhou Evid Based Complement Alternat Med Review Article OBJECTIVE: To systematically evaluate the efficacy and safety of Huangqin Tang (HQT) combined with mesalazine for the treatment of ulcerative colitis (UC). METHODS: The China Knowledge Network, Wanfang Data, VIP, PubMed, SinoMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) of UC with HQT in Chinese and English. The search time was from the establishment of the database to October 2021. The included literature was evaluated for data extraction and risk of bias, efficacy and safety were evaluated using the RevMan5.3 software, and the quality of evidence was evaluated using GRADE. RESULTS: Six studies with a total of 565 subjects were included, and a meta-analysis showed that HQT combined with mesalazine for UC significantly improved the cure rate (RR = 1.56, 95% CI [1.23, 1.98), P=0.0003) and overall efficacy rate (RR = 1.24, 95% CI [1.14, 1.35], P=0.00001), which significantly reduced the clinical symptom scores; however, all had high heterogeneity. HQT combined with mesalazine modulated the patients' serum IL-6, IL-10, IgA, and IgG levels. HQT combined with mesalazine for UC tended to reduce adverse effects; however, the difference was not statistically significant. All GRADE ratings of the quality of evidence were of low quality. CONCLUSIONS: HQT combined with mesalazine in the treatment of UC significantly improved the cure rate and overall treatment efficiency and regulated the expression levels of serum IL-6, IL-10, IgA, and IgG. Hindawi 2022-08-11 /pmc/articles/PMC9388247/ /pubmed/35990830 http://dx.doi.org/10.1155/2022/2175913 Text en Copyright © 2022 Chengyu Pan et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Pan, Chengyu Liu, Mengru Li, Hui Wei, Lanfu Wang, Pengcheng Wu, Kexuan Ji, Xing Gu, Limei Tian, Yaozhou Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis |
title | Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis |
title_full | Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis |
title_fullStr | Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis |
title_full_unstemmed | Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis |
title_short | Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis |
title_sort | systematic evaluation of randomized clinical trials of huangqin tang in combination with mesalazine for ulcerative colitis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388247/ https://www.ncbi.nlm.nih.gov/pubmed/35990830 http://dx.doi.org/10.1155/2022/2175913 |
work_keys_str_mv | AT panchengyu systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT liumengru systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT lihui systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT weilanfu systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT wangpengcheng systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT wukexuan systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT jixing systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT gulimei systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis AT tianyaozhou systematicevaluationofrandomizedclinicaltrialsofhuangqintangincombinationwithmesalazineforulcerativecolitis |